Understand the medicine
Check supply before building a plan around a brand.
An approval record is one question. Whether the exact product can be supplied is another. Both matter in a care discussion.
What to check
Ask which version the pharmacy can supply.
As of September 26, 2026, the FDA, the U.S. agency that reviews medicines, still lists liraglutide injection as in short supply nationally.
The same record lists some generics, meaning approved copies of a brand-name medicine, as available from their makers.
These include diabetes versions from Hikma and Meitheal and a diabetes copy sold by Teva under the Victoza approval.
Some versions can be available while others remain hard to find. Ask the pharmacy: Which exact version do you have, and is it for the use on my prescription?
Ask about the end of Saxenda shipments.
As of September 26, 2026, the maker plans its last liraglutide (Saxenda) shipments for late January 2027. These go to wholesalers, the businesses that supply pharmacies.
Ask what comes next if supply changes.
Which other options would we discuss if the pharmacy could no longer supply this product?
The maker attributes the planned liraglutide (Saxenda) withdrawal to a business decision, rather than a safety or quality concern.
A note before moving on
National status is not local stock
FDA’s shortage list concerns supply across the country; a pharmacy running out locally presents a separate supply problem.
Keep the date with any supply answer. Ask again when arranging care.
Open the record
Read this for the detail
- FDA’s liraglutide supply record
Find the exact product’s entry. Read its supply status beside the planned end of Saxenda shipments.
- FDA’s running supply and compounding updates
The entries explain why a national shortage listing matters beyond a local stock check.
Next reading card